Investing.com - Oragenics reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Oragenics announced earnings per share of $-0.0300 on revenue of $86.05K. Analysts polled by Investing.com anticipated EPS of $-0.0500 on revenue of $0.00.
Oragenics shares are down 57.42% from the beginning of the year , still down 69.62% from its 52 week high of $0.63 set on Monday, November 29, 2021.
Oragenics follows other major Healthcare sector earnings this month
Oragenics's report follows an earnings beat by Eli Lilly on Tuesday, November 1, 2022, who reported EPS of $1.98 on revenue of $6.94B, compared to forecasts EPS of $1.91 on revenue of $6.91B.
AbbVie had beat expectations on Friday, October 28, 2022 with third quarter EPS of $3.66 on revenue of $14.81B, compared to forecast for EPS of $3.58 on revenue of $14.93B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar